C
Confo Therapeutics
Drug discovery platform targeting previously inaccessible GPCRs
About Confo Therapeutics
Confo Therapeutics is a clinical-stage biopharmaceutical company that specializes in the discovery of medicines targeting G-protein coupled receptors (GPCRs). The company was spun out in 2015 from Vrije Universiteit Brussel (VUB) and the Flanders Institute for Biotechnology (VIB). Its foundation is based on the proprietary ConfoBody™ technology developed in the lab of Professor Jan Steyaert, a scientific founder of the company. This technology utilizes single-domain antibodies, or "ConfoBodies™," derived from camelids to stabilize GPCRs in specific, functionally relevant conformations that are otherwise inherently unstable. This stabilization allows for the identification of novel drug candidates against GPCR targets that were previously considered undruggable.
Read full description
The company's CEO is Dr. Cedric Ververken, who joined in 2016 from Ablynx, bringing experience in both R&D and business development. Confo Therapeutics focuses its internal pipeline on developing treatments for metabolic and endocrine diseases, including rare diseases and obesity. One of its lead candidates, CFTX-1554, is a non-opioid treatment for neuropathic pain that targets the angiotensin II type 2 receptor (AT2R). The business model involves advancing its own pipeline of drug candidates while also engaging in strategic collaborations with major pharmaceutical companies like Roche and Lundbeck. Revenue is generated through these partnerships and the potential future commercialization of its in-house developed therapeutics.
Confo Therapeutics has secured significant funding from an international consortium of life science investors. After initial seed funding, the company raised €30 million in a Series A round in 2019 and more recently, €60 million in a Series B financing in July 2024. This funding is aimed at advancing its lead programs through clinical trials and expanding its discovery platform to include small molecules and agonistic antibodies.
At a glance
- Founded
- 2015
- Headquarters
- Ghent, Belgium
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Capricorn Partners
Qbic Fund
VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen- FEFlemish Department for Innovation and Entrepreneurship
Series A13 investors entered at this stage
The Institute for the Promotion of Innovation by Science and Technology in Flanders
Wellington Partners
BioGeneration Ventures
PMV
V-Bio Ventures
Perceptive Advisors
Ackermans & van Haaren
BioGenerator
FundPlus
University of Michigan
Quest for Growth
Flanders Institute for Biotechnology
Driehaus Capital Management
Series B and later8 investors entered at this stage
- AHAckermans & van Haaren
- BIBioGenerator
- FBFlanders Institute for Biotechnology
- QGQuest for Growth
- DMDriehaus Capital Management
- VBVrije Universiteit Brussel
- FUFundPlus
- UMUniversity of Michigan
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Confo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Confo Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.